No Data
PTC Therapeutics (NASDAQ:PTCT) Delivers Shareholders Notable 96% Return Over 1 Year, Surging 7.5% in the Last Week Alone
RBC Capital Remains a Hold on PTC Therapeutics (PTCT)
PTC Therapeutics ALS Drug Fails to Meet Endpoints as Trials Shut Down
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $52
Baird Maintains Outperform on PTC Therapeutics, Raises Price Target to $52
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long